| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Monday, December 10, 2018 4:44:15 PM
cmm...
Thank you...Would our efforts be better spent educating the insurance carriers Rather than the public?...Good question..
I would say "no" for one important reason...There are more who qualify as interested public than there are who qualify as policy makers for insurance companies. Insurance companies have access to the same information we do and there is no question they know about R-I and that they know the difference between Lovaza and Vascepa...My insurance company was changed to CVS Silver Scrips and was changed from Teir 4 to Tier 2...When my PCP asked for a review...And I did not have high trigs...
Insurance companies will try to get away with everything they can if no one challenges them...Look at the life insurance scandal when the insurance companies kept the insurance money on policies if the beneficiary did not make a claim..Even though the insurance companies knew who the beneficiaries were...
Insurance companies will throw anything they get from a "lay blog" right in the shredder and won't spend one minute reading it..The insurance companies already know all about R-I and it's lifesaving benefits...and also know Lovaza is piss, but they are not in for the love of the fellow man..Right now they can save money by giving people a placebo and if the patient has a heart attack he did not need...Well its the doctors, the FDA at fault...If they took Lovaza off the market and mandated Vascepa don't worry, the insurance companies would be paying for it...
Right now we have a better chance of educating consumers and maybe its only a little thing, but if we can save a life here or there we are not wasting our time...
":>) JL
Thank you...Would our efforts be better spent educating the insurance carriers Rather than the public?...Good question..
I would say "no" for one important reason...There are more who qualify as interested public than there are who qualify as policy makers for insurance companies. Insurance companies have access to the same information we do and there is no question they know about R-I and that they know the difference between Lovaza and Vascepa...My insurance company was changed to CVS Silver Scrips and was changed from Teir 4 to Tier 2...When my PCP asked for a review...And I did not have high trigs...
Insurance companies will try to get away with everything they can if no one challenges them...Look at the life insurance scandal when the insurance companies kept the insurance money on policies if the beneficiary did not make a claim..Even though the insurance companies knew who the beneficiaries were...
Insurance companies will throw anything they get from a "lay blog" right in the shredder and won't spend one minute reading it..The insurance companies already know all about R-I and it's lifesaving benefits...and also know Lovaza is piss, but they are not in for the love of the fellow man..Right now they can save money by giving people a placebo and if the patient has a heart attack he did not need...Well its the doctors, the FDA at fault...If they took Lovaza off the market and mandated Vascepa don't worry, the insurance companies would be paying for it...
Right now we have a better chance of educating consumers and maybe its only a little thing, but if we can save a life here or there we are not wasting our time...
":>) JL
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
